Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn

Authors

  • Muhammad W. Saif, MD

Keywords:

nab-paclitaxel and fluorouracil, leucovorin, oxalipla-tin, and irinotecan

Abstract

The American Cancer Society’s estimates that 57,600 people (30,400 men and 27,200 women) will be diagnosed with pan-creatic cancer in the United States for 2020 and approximately 47,050 people (24,640 men and 22,410 women) will die of pancre-atic cancer in 2020.1 Despite advances in first-line therapy such as gemcitabine/nab-paclitaxel and fluorouracil, leucovorin, oxalipla-tin, and irinotecan (FOLFIRINOX) in advanced pancreatic cancer (aPC), median overall survival remains less than 12-months.

Downloads

Published

2025-09-09

How to Cite

Muhammad W. Saif, MD. (2025). Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn. Pancreas, 4(1), 1–2. Retrieved from https://openventio.us/index.php/POJ/article/view/1174

Issue

Vol. 4 No. 1 (2020): Volume 4 Issue 1 2020

Section

Articles

License

All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.